Guilin Rhine Biotechnology Co., Ltd.
Securities Code: 002166
Securities Abbreviation: Rhine Biotechnology
Announcement No.: 2026-025
Guilin Rhine Biotechnology Co., Ltd. Progress Announcement on Providing Guarantees for Wholly-Owned Subsidiaries
The company and all members of the board guarantee that the content of this information disclosure is true, accurate, and complete, without false records, misleading statements, or significant omissions.
I. Overview of External Guarantee Progress
(1) Recent External Guarantee Situation
Recently, Guilin Rhine Biotechnology Co., Ltd. (hereinafter referred to as "the Company") signed a "Guarantee Contract" with Chengdu Rural Commercial Bank Co., Ltd. Pujiang Branch (hereinafter referred to as "Chengdu Rural Commercial Bank Pujiang Branch") and a "Maximum Guarantee Contract" with Chengdu Bank Co., Ltd. Pujiang Branch (hereinafter referred to as "Chengdu Bank Pujiang Branch") to provide joint liability guarantees for its holding subsidiary Chengdu Huagao Biological Products Co., Ltd. (hereinafter referred to as "Huagao Biological") for a loan application of RMB 10 million from Chengdu Rural Commercial Bank Pujiang Branch and a comprehensive credit application of RMB 10 million from Chengdu Bank Pujiang Branch. Other shareholders of Huagao Biological have provided equivalent guarantees for the above-mentioned guarantee matters and have provided counter-guarantees to the Company within their shareholding ratio.
(2) Review of External Guarantee
On March 27, 2026, the Company held the 11th meeting of the 7th Board of Directors, which reviewed and approved the proposal on the estimated guarantee limit for subsidiaries in 2026. The board agreed to provide guarantees for the wholly-owned subsidiary Guilin Rhine Health Technology Co., Ltd. and the holding subsidiary Chengdu Huagao Biological Products Co., Ltd. for applications for comprehensive credit from financial institutions (including but not limited to extensions or new loans, acceptance bills, order financing, etc.) with a limit not exceeding RMB 10 million and RMB 10 million, respectively. The board authorized the chairman of the Company to be responsible for this matter and sign relevant agreement documents within the above limits, with the authorization period valid for one year from the date of this board meeting approval. The guarantee limit can be reused within its validity period, and the guarantee balance at any point in time shall not exceed the guarantee limit approved by this board meeting. For specific details, please refer to the announcement disclosed by the Company on March 31, 2026, regarding the estimated guarantee limit for subsidiaries in 2026 (Announcement No.: 2026-011). The guarantee provided for the holding subsidiary Huagao Biological is within the review limit approved at the 11th meeting of the 7th Board of Directors. After this guarantee, the actual guarantee balance for Huagao Biological is RMB 95 million (already provided and still within the guarantee period), accounting for 3.01% of the Company's latest audited net assets, with a remaining available guarantee limit of RMB 5 million.